Buy Vytorin through the unique service that maximize your savings

M2 PRESSWIRE-17 February 2006-Research and Markets: Pfizers Atorvastatin Torcetrapib Combination is Expected to Have a Major Impact on the Dyslipidemia Market and is Expected to Compete with Both Atorvastatin and Vytorin(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:17022006 Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c33178) has announced the addition of Commercial Insight: Antidyslipidemics - Statins Hit …

2 de septiembre de 2008 — Datos recientes que sugieren que el frmaco para
reducir el colesterol
Vytorin aumenta el riesgo de cncer no pueden an ser descartados, afirma
el editor de la revista The New England Journal of Medicine.
Los inquietantes datos sobre el cncer provienen de un ensayo clnico
llamado SEAS, presentados hoy en una importante con…

New research finds no definitive link between Vytorin and cancer risk, but it also suggests that the cholesterol-lowering drug cannot curb cardiovascular disease.
The results of a small study published recently suggested that Vytorin (ezetimibe) might boost the chances of developing cancer. In that study, called SEAS, researchers found that among patients taking Vytorin, 101 developed cancer, compared with 65 in the control grou…

REPS. JOHN Dingell and Bart Stupak aren’t only interested in Lipitor advertising. In the wake of the release of ENHANCE trial data, the duo sent letters to Merck and Schering-Plough vowing an investigation and making clear that DTC ads for the …

Byline: RICH THOMASELLI
The video shows the oh-so-familiar commercial for cholesterol drug Vytorin, in which benign-looking “aunts” and “uncles” are dressed up to look like platefuls of fatty foods. What’s different, however, is the voice-over: “Nobody knows if Vytorin is safe or effective, but with enough sc…

Greater LDL Cholesterol Reduction with VYTORIN Compared to Lipitor Resulted in Greater LDL Cholesterol Goal Attainment
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J. — Results from a clinical study conducted in 1,229 patients with type II diabetes mellitus and high cholesterol …

WHITEHOUSE STATION & KENILWORTH, N.J. — Large Trial to Evaluate VYTORIN(TM) in Reducing Major Cardiovascular Events Through Intensive Lowering of LDL Cholesterol in Patients with Acute Coronary Syndromes
Merck/Schering-Plough Pharmaceuticals today announced a large scale clinical outcomes trial that will be conducted for VYTORIN(TM) (ezetimibe/simvastatin). The trial known as IMPROVE…

First came the negative publicity, then the lawsuits. Merck & Co. and Schering Plough Corp., makers of the cholesterol-lowering combination drug Vytorin, are getting hit with a wave of lawsuits asserting the companies knew its product didn't work and delayed telling the public about it. At least 10 lawsuits have been filed in federal courts, with half the filings in New Jersey, where both parent companies are based.

Related Results

…

WHITEHOUSE STATION and KENILWORTH, N.J. — Greater LDL Cholesterol Reduction with VYTORIN-TM- Compared to Lipitor Resulted in Greater Goal Attainment At Most Common Doses
Results from a new clinical trial conducted in 1,902 patients with high cholesterol showed that VYTORIN(TM) (ezetimibe/simvastatin) provided greater reduction in LDL (”bad”) cholesterol across the dosing ranges compared to Lipitor. At the most commonly used starting doses of these two therapies, VYTORIN 10/20 mg decreas…